Pulmatrix has announced the results of a clinical study showing that an iCALM (inhaled cationic airway lining modulator therapy) attenuated allergen-induced bronchitis in susceptible asthmatic patients. The study concluded that iCALM is a ...
Pulmatrix, a developer of inhalable drug delivery platforms, has appointed Robert Clarke as the company's new chief executive officer (CEO). Previously, Clarke served as the company's chief scientific officer and vice president of ...